ArticleDrug design, development and therapy2026
Real-World Outcomes and Safety of PD-1 Blockade Rechallenge Strategies After Prior Immunotherapy in Advanced NSCLC: A Retrospective Cohort Study.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Evidence to guide treatment after progression on immunotherapy remains limited in advanced non-small cell lung cancer (NSCLC). We descriptively report real-world outcomes of two PD-1 rechallenge strategies (PD-1 plus chemotherapy and PD-1 plus anlotinib) using a contemporaneous docetaxel cohort as contextual reference. Methods: Patients with advanced NSCLC who failed prior immunotherapy were screened retrospectively, 33 patients received PD-1 blockade plus chemotherapy, 31 received PD-1 blockade plus anlotinib and 63 patients treated with docetaxel monotherapy were served as a contextual reference cohort. Outcomes including objective response rate (ORR), disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAEs) were summarized by cohort. Survival outcomes were estimated using Kaplan-Meier methods. Results: ORR and DCR were 30.3% (95% CI: 15.6%-48.7%) and 84.8% (95% CI: 68.1%-94.9%) in PD-1 plus chemotherapy cohort, 22.6% (95% CI: 9.6%-41.1%) and 80.6% (95% CI: 62.5%-92.5%) in PD-1 plus anlotinib cohort, 15.9% (95% CI: 7.9%-27.3%) and 54.0% (95% CI: 40.9%-66.6%) in docetaxel cohort. Median DoR among responders was 6.9 months (95% CI: 0.7-13.1), 7.1 months (95% CI: 5.0-9.2), and 3.1 months (95% CI: 1.9-4.3), respectively. Median PFS was 7.0 months (95% CI: 0.7-13.3), 6.5 months (95% CI: 2.2-10.8), and 3.3 months (95% CI: 2.2-4.4), and median OS was 17.8 months (95% CI: 8.0-27.6), 16.8 months (95% CI: 13.9-19.7), and 9.5 months (95% CI: 4.8-14.2), respectively. Any-grade TRAEs occurred in 84.8%, 80.6%, and 81.0%, and grade ≥3 TRAEs were 42.4%, 41.9%, and 34.9%, respectively. No treatment-related deaths were observed. Conclusion: PD-1 rechallenge strategies showed measurable antitumor activity and manageable safety profile in a subset of previously immunotherapy-treated advanced NSCLC. Limitations existed in this study and the findings were descriptive and hypothesis-generating and should be interpreted cautiously because treatment selection was non-random and important confounders might be incompletely captured.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.